CN Survey 1110

Article

Offer Terms: Offer available only to licensed physicians who register as members of CancerNetwork.com prior to November 30, 2010, subject to UBM Medica's verification of member's licensure status. Registrants must be (i) legal residents of the fifty United States (and the District of Columbia), (ii) at least 18 years of age, and (iii) licensed physicians, as of the date of their registration. Employees of UBM Medica, its parent company, affiliates and subsidiaries, and their agents, subcontractors, suppliers, as well as the immediate family (spouse, parents, siblings, and children) and household members of each such employee are not eligible to receive incentive. Limit 1 gift card per person. Offer is not retroactive to previously registered members. The gift card code will be e-mailed to you within 7 - 10 business days of November 30, 2010 at the e-mail address on file with UBM Medica (in user’s member profile). E-mail address on file must be a valid, working e-mail address in order to receive incentive.  

 

Thank you for registering to CancerNetwork.com. 

 

Click here to participate in the survey

Offer Terms: Offer available only to licensed physicians who register as members of CancerNetwork.com prior to November 30, 2010, subject to UBM Medica's verification of member's licensure status. Registrants must be (i) legal residents of the fifty United States (and the District of Columbia), (ii) at least 18 years of age, and (iii) licensed physicians, as of the date of their registration. Employees of UBM Medica, its parent company, affiliates and subsidiaries, and their agents, subcontractors, suppliers, as well as the immediate family (spouse, parents, siblings, and children) and household members of each such employee are not eligible to receive incentive. Limit 1 gift card per person. Offer is not retroactive to previously registered members. The gift card code will be e-mailed to you within 7 - 10 business days of November 30, 2010 at the e-mail address on file with UBM Medica (in user’s member profile). E-mail address on file must be a valid, working e-mail address in order to receive incentive.
 

 

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
1 expert is featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
5 experts are featured in this series
5 experts are featured in this series
2 experts in this video
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
2 experts in this video
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Related Content